Matthew Cooperberg, MD | Authors

Articles

Dr. Matthew Cooperberg on the Effectiveness of Active Surveillance in Prostate Cancer

February 13, 2016

Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.

Dr. Matthew Cooperberg on New Aspects of the Treatment Paradigm for Prostate Cancer

February 03, 2016

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the appropriateness of a more aggressive approach to men with high-risk prostate cancer. Cooperberg says currently, men will normally respond to surgery followed by adjuvant radiotherapy, as well as systemic therapy.

Impact of Immunotherapy on the Treatment of Prostate Cancer

August 06, 2015

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the impact of immunotherapy on the treatment of prostate cancer. Cooperberg believes immunotherapy treatment should be used earlier in the course of the disease.